Clinical Trials Logo
  1. Home
  2. HIV I Infection
  3. NCT04725877

VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers

HIV I Infection Clinical Trial

Official title:
A Phase 1a, Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of a Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers

Clinical Trial Summary

This is a Phase 1a, first in human study in which healthy adult participants who are considered to be at low-risk for HIV infection and are seropositive for cytomegalovirus (CMV) will receive two doses of VIR-1111 or placebo. These participants will be assessed for safety, reactogenicity, tolerability and immunogenicity. There is an optional long-term follow-up study that would lengthen study participation for up to 3 years post-first dose.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04725877
Study type Interventional
Source Vir Biotechnology, Inc.
Contact
Status Completed
Phase Phase 1
Start date December 28, 2020
Completion date December 5, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT04585737 - Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF Phase 4
Not yet recruiting NCT06282783 - Studying Topiramate for Re-Activating the HIV-1 Reservoir Phase 1/Phase 2
Not yet recruiting NCT03622177 - Role of the IL33/Amphiregulin Pathway as a Potential Therapeutic Target in HIV Infection
Recruiting NCT05854381 - To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV Phase 1
Enrolling by invitation NCT05071378 - Leveraging Family-Based Assets for Black MSM In House Ball Communities N/A
Completed NCT05421806 - A Cohort Study of Use of Doravirine (DOR) Based Regimens in Clinical Practice in Europe DoRavirine Europe Real World/
Completed NCT04568395 - Acute Effects of TCIG vs ECIG in PLWH N/A
Recruiting NCT04887675 - Neuroinflammation and Neurodegeneration in HIV-positive Subjects Switched and Initially Treated With INSTI N/A
Recruiting NCT04820933 - Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV Early Phase 1
Completed NCT03584048 - Charlotte Retention in Care Study
Recruiting NCT06005610 - Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy Phase 2
Recruiting NCT05947890 - Evaluating the Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living With and Without HIV in South Africa Phase 2
Recruiting NCT05187429 - Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy Phase 1/Phase 2
Active, not recruiting NCT05601128 - A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA Phase 3
Completed NCT04675255 - Assessing the Impact of INSTI to PI Switch on Insulin Sensitivity and Fat Metabolism N/A
Recruiting NCT05110963 - Intervention to Improve HIV Care Retention by Addressing Stigma Stigmatized Environments N/A
Completed NCT03986099 - Community Based Antiretroviral Therapy (CBART) Among Children on Chronic ART N/A
Completed NCT04971343 - Access HIV Ag/Ab Combo Assay - European Union (EU) Clinical Trial Protocol
Recruiting NCT04618198 - Early Empiric Anti-Mycobacterium Tuberculosis Therapy for Sepsis in Sub-Saharan Africa Phase 3
Completed NCT05383456 - The Visceral Adiposity Measurement and Observation Study